Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

CareDx Inc Stock Research

CDNA

7.36USD-0.28(-3.66%)Market Closed
Watchlist

Market Summary

USD7.36-0.28
Market Closed
-3.66%

CDNA Alerts

CDNA Stock Price

CDNA RSI Chart

CDNA Valuation

Market Cap

397.5M

Price/Earnings (Trailing)

-4.73

Price/Sales (Trailing)

1.29

EV/EBITDA

-4.42

Price/Free Cashflow

1.4K

CDNA Price/Sales (Trailing)

CDNA Profitability

EBT Margin

-25.09%

Return on Equity

-19.22%

Return on Assets

-15.28%

Free Cashflow Yield

0.07%

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

309.3M

Revenue Y/Y

-12.81%

Revenue Q/Q

-9.01%

CDNA Earnings

Earnings (TTM)

-84.0M

Earnings Y/Y

-15.01%

Earnings Q/Q

-5.07%

Price Action

52 Week Range

6.2220.71
(Low)(High)

Last 7 days

-8.2%

Last 30 days

-15.7%

Last 90 days

-16.1%

Trailing 12 Months

-54.6%

CDNA Financial Health

Current Ratio

5.17

CDNA Investor Care

Shares Dilution (1Y)

1.43%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for CDNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-07
Jain Abhishek
sold (taxes)
-22,682
8.26
-2,746
chief financial officer
2023-09-07
Ronai Abraham
sold (taxes)
-12,100
8.26
-1,465
see remarks
2023-09-06
Jain Abhishek
sold (taxes)
-9,285
8.81
-1,054
chief financial officer
2023-09-05
Seeto Reginald
sold
-26,762
9.4935
-2,819
see remarks
2023-08-14
Seeto Reginald
sold
-5,122
8.8935
-576
see remarks
2023-08-11
Bickerstaff George
acquired
99,064
5.09252
19,453
-
2023-08-07
Seeto Reginald
sold (taxes)
-7,279
10.8
-674
see remarks
2023-08-07
Johnson Alexander L
sold (taxes)
-2,343
10.8
-217
chief business officer
2023-08-02
Seeto Reginald
sold
-31,987
11.3472
-2,819
see remarks
2023-07-19
Johnson Alexander L
sold (taxes)
-11,955
10.28
-1,163
chief business officer

1–10 of 50

Which funds bought or sold CDNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
added
4.56
-41,000
1,436,000
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.17
-54,405
548,497
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-14.73
-40,564
155,431
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-50.7
-1,375,930
1,165,070
-%
2023-08-15
Belpointe Asset Management LLC
sold off
-100
-3,519
-
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
12.73
27,871
604,605
-%
2023-08-15
Bullseye Asset Management LLC
unchanged
-
-96,000
1,273,000
0.64%
2023-08-15
GOLDMAN SACHS GROUP INC
added
17.37
612,612
7,305,630
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
sold off
-100
-18,000
-
-%
2023-08-15
WELLS FARGO & COMPANY/MN
reduced
-0.45
-55,990
698,700
-%

1–10 of 48

Latest Funds Activity

Are funds buying CDNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDNA
No. of Funds

Schedule 13G FIlings of CareDx

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jul 07, 2023
blackrock inc.
10.1%
5,439,512
SC 13G/A
Mar 13, 2023
gagnon securities llc
4.7%
2,522,063
SC 13G
Feb 15, 2023
arrowmark colorado holdings llc
7.48%
4,003,218
SC 13G
Feb 14, 2023
bellevue asset management (uk) ltd.
5.9%
3,168,448
SC 13G
Feb 10, 2023
ark investment management llc
11.56%
6,188,182
SC 13G/A
Feb 09, 2023
vanguard group inc
9.84%
5,270,397
SC 13G/A
Feb 08, 2023
invesco ltd.
0.2%
88,421
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
4,373,662
SC 13G/A
Jan 10, 2023
state street corp
10.74%
5,747,244
SC 13G/A
Jan 10, 2023
alger associates inc
0.9%
503,686
SC 13G/A

Recent SEC filings of CareDx

View All Filings
Date Filed Form Type Document
Sep 26, 2023
4
Insider Trading
Sep 26, 2023
8-K
Current Report
Sep 25, 2023
8-K
Current Report
Sep 11, 2023
4
Insider Trading
Sep 11, 2023
4
Insider Trading
Sep 08, 2023
4
Insider Trading
Sep 05, 2023
144
Notice of Insider Sale Intent
Sep 05, 2023
4
Insider Trading
Aug 14, 2023
144
Notice of Insider Sale Intent
Aug 14, 2023
4
Insider Trading

CDNA Fair Value

Loading...

Peers (Alternatives to CareDx)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
272.0B
56.0B
4.92% 10.10%
31.31
4.85
-2.31% -31.27%
90.7B
9.5B
0.47% 27.06%
26.94
9.54
13.83% 5.33%
89.1B
12.7B
0.25% 21.32%
20.72
7.03
-10.94% -24.40%
13.2B
3.5B
-7.17% -10.43%
36.13
3.77
5.81% -61.22%
MID-CAP
5.1B
931.0M
-21.63% 5.69%
-10.02
5.51
28.69% 11.08%
2.8B
256.2M
-6.13% -11.58%
-15.49
10.95
2.51% -17.66%
SMALL-CAP
1.6B
328.6M
-11.21% 30.44%
-56.44
4.99
22.46% 40.27%
430.3M
167.5M
-13.77% -32.41%
-4.84
2.57
52.01% -99.69%
397.5M
309.3M
-15.69% -54.62%
-4.73
1.29
-1.76% -21.01%
340.1M
457.3M
-2.63% -17.52%
33.85
0.74
-0.61% -85.93%
212.5M
-
-2.68% 7.78%
-4.34
-
- -59.74%
164.1M
493.9M
-30.95% -74.20%
-0.21
0.33
-1.39% 74.28%
1.5M
2.8M
28.48% -44.24%
-0.04
0.54
-31.25% -41.90%

CareDx News

Defense World
CareDx (NASDAQ:CDNA) Receives Equal Weight Rating from ....
Defense World,
4 hours ago
Business Wire
Seeking Alpha
Icosavax GAAP EPS of -$0.59.
Seeking Alpha,
43 days ago
Business Wire

Returns for CDNA

Cumulative Returns on CDNA

10.7%


7-Year Cumulative Returns

-23.2%


5-Year Cumulative Returns

-39.2%


3-Year Cumulative Returns

Risks for CDNA

What is the probability of a big loss on CDNA?

100%


Probability that CareDx stock will be more than 20% underwater in next one year

95%


Probability that CareDx stock will be more than 30% underwater in next one year.

57.7%


Probability that CareDx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CareDx was unfortunately bought at previous high price.

Drawdowns

Financials for CareDx

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-3.2%309,306,000319,639,000321,793,000318,629,000314,859,000308,413,000296,397,000275,821,000253,601,000221,214,000192,194,000169,371,000149,813,000139,466,000127,068,000114,756,000102,129,00088,498,00076,569,00065,563,00056,570,000
Gross Profit-------------98,186,00091,352,00081,613,00071,508,00061,488,00052,162,00043,582,00045,826,00042,464,000
Operating Expenses-1.1%397,713,000402,141,000399,024,000392,139,000379,757,000356,334,000326,123,000293,215,000265,175,000238,849,000214,722,000194,377,000178,659,000152,841,000151,600,000137,391,000111,849,000100,888,00092,147,00045,548,00046,587,000
  S&GA Expenses-5.5%90,790,00096,110,00096,027,00093,183,00092,292,00084,941,00077,245,00072,552,00065,052,00057,587,00053,858,00047,994,00045,182,00043,692,00038,894,00034,381,00029,294,00024,510,00021,670,00018,977,00016,261,000
  R&D Expenses-2.6%90,466,00092,865,00090,388,00088,864,00085,997,00082,401,00076,525,00067,804,00060,839,00054,932,00048,941,00044,562,00040,609,00035,110,00030,711,00025,547,00020,894,00016,760,00014,514,00013,760,00012,851,000
EBITDA100.0%--67,788,000-64,631,000--60,459,000-41,331,000-23,290,000---7,230,000-12,734,000-14,288,000-14,340,000-15,930,000-18,402,000-16,270,000-34,214,000-40,823,000---
EBITDA Margin100.0%--0.21-0.20--0.19-0.13-0.08---0.03-0.07-0.08-0.10-0.11-0.14-0.14-0.34-0.46---
Interest Expenses---8,000---1,000---10,000---22,000---1,774,000--
Earnings Before Taxes-4.1%-83,474,000-80,199,000-76,234,000-75,130,000-70,517,000-50,798,000-32,088,000-18,722,000-9,716,000-14,577,000-19,750,000-21,045,000-20,754,000-21,933,000-23,947,000-23,060,000-40,558,000-46,934,000-48,215,000-76,622,000-70,827,000
EBT Margin100.0%--0.25-0.24-0.24-0.22-0.16-0.11-0.07-0.04-0.07-0.10-0.12-0.14-0.16-0.19------
Net Income-4.0%-83,970,000-80,714,000-76,613,000-74,435,000-69,393,000-49,623,000-30,662,000-18,026,000-8,947,000-13,578,000-18,714,000-19,976,000-18,971,000-20,260,000-21,968,000-20,946,000-39,103,000-45,318,000-46,756,000-74,672,000-68,970,000
Net Income Margin100.0%--0.25-0.24-0.23-0.22-0.16-0.10-0.07-0.04-0.06-0.10-0.12-0.13-0.15-0.17------
Free Cashflow100.0%--3,100,000-25,239,000-28,258,000-20,797,000-17,413,333-29,575,333-26,560,333-21,219,333-5,432,00024,537,66716,273,66715,441,000-2,798,333-4,699,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.5%51552854354554154756756355754136935434515715214514312813191.0080.00
  Current Assets-2.9%36137138838840441143344544143927325925266.0072.0068.0068.0078.0081.0042.0031.00
    Cash Equivalents17.6%88.0075.0090.0083.0016717234935333630913521421132.0038.0041.0044.0058.0065.0026.0016.00
  Inventory4.6%19.0018.0019.0018.0019.0018.0017.0019.0015.0014.0010.0010.009.007.006.006.005.005.005.005.005.00
  Net PPE--------19.0014.0011.0011.0010.007.006.004.004.004.004.004.003.002.00
  Goodwill0.1%40.0040.0038.0038.0037.0037.0037.0026.0026.0026.0024.0024.0024.0024.0024.0024.0023.0012.0012.00--
Liabilities1.3%11010811210898.0089.0010191.0078.0070.0091.0085.0084.0055.0053.0047.0050.0032.0035.0047.0051.00
  Current Liabilities3.7%74.0072.0076.0070.0078.0067.0077.0070.0056.0046.0069.0062.0057.0028.0035.0031.0029.0016.0020.0016.0014.00
    LT Debt, Current----------------------
    LT Debt, Non Current--------------------13.0013.00
Shareholder's Equity-3.5%40542043143744445846647248047227826926110199.0098.0093.0096.0096.0044.0029.00
  Retained Earnings-5.2%-509-484-460-441-424-402-383-367-355-353-352-349-346-339-333-329-327-319-311-308-288
  Additional Paid-In Capital1.2%924912899887875865854843838828632622612448438432425420412356321
Shares Outstanding0.7%54.0054.0054.0054.0053.0053.0053.0053.0052.0051.0049.0049.0045.0043.0042.0042.0042.0042.0041.0037.0036.00
Minority Interest----------------------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations109.0%278-3,100-25,239-28,258-20,797-7,132-19,294-16,279-11,4542,85633,43125,16720,56543.00-2,769312106-5,356-4,007-8,155-10,774
  Share Based Compensation0.2%49,78049,67346,55343,92543,36340,16836,08132,56028,67025,68923,40122,83122,04820,62322,41719,07014,96612,4857,1385,5064,075
Cashflow From Investing16.7%-72,683-87,241-228,502-238,759-142,822-127,39947,712-34,980-59,418-79,611-100,394-11,262-10,541-23,740-22,579-22,197-19,296-7,718-7,929-12,005-12,366
Cashflow From Financing6.6%-6,107-6,538-4,535-2,997-5,099-2,721185,642190,440194,797353,112163,149159,267158,789-179-13237,09846,55051,89850,26830,87620,786
  Buy Backs9.7%1,5141,380642----------------2,224-

CDNA Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 70,301,000$ 80,634,000$ 147,563,000$ 160,050,000
Operating expenses:    
Research and development20,233,00022,632,00044,590,00044,512,000
Sales and marketing21,630,00026,950,00044,861,00050,098,000
General and administrative29,327,00025,232,00057,359,00051,791,000
Restructuring costs848,0000848,0000
Total operating expenses97,925,000102,353,000199,511,000200,822,000
Loss from operations(27,624,000)(21,719,000)(51,948,000)(40,772,000)
Other income (expense):    
Interest income, net2,871,000478,0005,537,000667,000
Change in estimated fair value of common stock warrant liability3,00048,00010,00075,000
Other expense, net(271,000)(553,000)(2,245,000)(1,376,000)
Total other income (expense)2,603,000(27,000)3,302,000(634,000)
Loss before income taxes(25,021,000)(21,746,000)(48,646,000)(41,406,000)
Income tax benefit (expense)68,00049,000(56,000)61,000
Net loss$ (24,953,000)$ (21,697,000)$ (48,702,000)$ (41,345,000)
Net loss per share    
Basic (in dollars per share)$ (0.46)$ (0.41)$ (0.91)$ (0.78)
Diluted (in dollars per share)$ (0.46)$ (0.41)$ (0.91)$ (0.78)
Weighted-average shares used to compute net loss per share:    
Basic (in shares)53,846,26053,249,54553,745,29953,133,149
Diluted (in shares)53,846,26053,249,54553,745,29953,133,149
Testing services revenue    
Revenue:    
Total revenue$ 53,414,000$ 67,135,000$ 115,198,000$ 133,579,000
Operating expenses:    
Cost of testing services, product, digital, and other15,324,00018,230,00030,620,00035,858,000
Product revenue    
Revenue:    
Total revenue7,876,0006,714,00014,737,00013,502,000
Operating expenses:    
Cost of testing services, product, digital, and other3,926,0003,887,0007,992,0008,286,000
Patient and digital solutions revenue    
Revenue:    
Total revenue9,011,0006,785,00017,628,00012,969,000
Operating expenses:    
Cost of testing services, product, digital, and other$ 6,637,000$ 5,422,000$ 13,241,000$ 10,277,000

CDNA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 87,786$ 89,921
Marketable securities194,887203,168
Accounts receivable51,62566,312
Inventory18,84019,232
Prepaid and other current assets7,6769,216
Total current assets360,814387,849
Property and equipment, net36,08435,529
Operating leases right-of-use assets32,11834,689
Intangible assets, net43,52943,051
Goodwill39,65537,523
Restricted cash584522
Other assets2,0363,828
Total assets514,820542,991
Current liabilities:  
Accounts payable9,8809,942
Accrued compensation14,44116,902
Accrued and other liabilities50,17549,131
Total current liabilities74,49675,975
Deferred tax liability510
Common stock warrant liability032
Deferred payments for intangible assets4,2242,418
Operating lease liability, less current portion30,58933,406
Other liabilities247249
Total liabilities109,607112,080
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock: $0.001 par value; 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 202200
Common stock: $0.001 par value; 100,000,000 shares authorized at June 30, 2023 and December 31, 2022; 54,013,601 shares issued and outstanding at June 30, 2023; 53,583,301 shares issued and 53,533,250 shares outstanding at December 31, 20225252
Additional paid-in capital923,514898,806
Accumulated other comprehensive loss(8,450)(7,503)
Accumulated deficit(509,903)(460,444)
Total stockholders’ equity405,213430,911
Total liabilities and stockholders’ equity$ 514,820$ 542,991
Reginald Seeto
640
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.